SCHEMBL1663211

SCHEMBL1663211

Nc1ccc(-c2n[nH]c3ccc(N)cc23)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 3/20 0.60
FGFR1 P11362 1/20 0.57
FGFR2 P21802 1/20 0.57
HTR2A P28223 1/20 0.55
HTR2C P28335 1/20 0.55
HTR2B P41595 1/20 0.55
AURKA O14965 1/20 0.53
MAP2K4 P45985 6/20 0.51
MAPK1 P28482 4/20 0.51
MAPKAPK3 Q16644 4/20 0.51
MAPK6 Q16659 4/20 0.51
MAPKAPK2 P49137 3/20 0.51
MAPKAPK5 Q8IW41 2/20 0.51
MKNK1 Q9BUB5 1/20 0.51
JAK2 O60674 3/20 0.50
DCLK1 O15075 1/20 0.50
PRKD3 O94806 1/20 0.50
MAP4K4 O95819 1/20 0.50
CHEK2 O96017 1/20 0.50
CSF1R P07333 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2469031 0.90 AXL (0.55) AXLFGFR1FGFR2HTR2AHTR2C
SCHEMBL4006856 0.90 AXL (0.55) AXLFGFR1FGFR2HTR2AHTR2C
SCHEMBL31423230 0.89 DCLK1 (0.65) AXLHTR2AHTR2CHTR2BAURKA
SCHEMBL4008208 0.89 DCLK1 (0.65) AXLHTR2AHTR2CHTR2BAURKA
SCHEMBL12193658 0.89 MKNK1 (0.61) AXLFGFR1FGFR2HTR2AHTR2C
Hydrochloric Acid SCHEMBL27750634 0.88 AXL (0.54) AXLFGFR1FGFR2HTR2AHTR2C
SCHEMBL1663652 0.86 FGFR1 (0.68) AXLFGFR1FGFR2HTR2AHTR2C
SCHEMBL4009086 0.85 AXL (0.55) AXLHTR2AHTR2CHTR2BMAP2K4
SCHEMBL1664137 0.85 LRRK2 (0.58) AXLFGFR1FGFR2HTR2AHTR2C
SCHEMBL1663819 0.85 FGFR1 (0.71) AXLFGFR1FGFR2AURKAMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
EP-2642994-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS Ligand Pharmaceuticals Incorporated (US) 2013-10-02 EP disclosed
EP-2488486-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES Ligand Pharmaceuticals Inc. (US) 2012-08-22 EP disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL AXL 1200/4885FGFR1 129/4885FGFR2 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.